Catecholamine Derivatives for Oral Bioavailability in Parkinson's Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases like Parkinson's and Huntington's lack effective, orally active drugs that provide sustained dopaminergic stimulation with minimal side effects, and existing catecholamine derivatives face challenges due to high first-pass metabolism and low oral bioavailability.
Innovation Solution
Development of novel catecholamine derivatives that act as potent dopamine D1-like and D2-like agonists, designed for oral administration, which can also serve as PET ligands for imaging studies, offering improved bioavailability and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If catecholamine derivatives are used as dopamine agonists, then dopaminergic activity is achieved, but oral bioavailability is low due to high first-pass metabolism
Solution Approach 1:
The patent modifies the chemical structure of catecholamine derivatives by introducing specific substituents at positions 6 and 7 of the benzene ring (such as fluorine, chlorine, methyl, or methoxyl groups) and varying the alkyl chains at positions 1 and 2. These structural parameter changes reduce first-pass metabolism while maintaining dopaminergic activity, thereby improving oral bioavailability.
Solution Approach 2:
The invention creates composite molecular structures combining the core catecholamine framework with various aromatic substituents and alkyl chains. This composite approach allows optimization of pharmacokinetic properties while preserving the essential dopaminergic pharmacological activity.
2Reliability
If L-DOPA is administered to replace dopamine, then dopaminergic activity is improved, but dyskinesia and response fluctuations occur
Solution Approach 1:
The patent develops direct dopamine receptor agonists that act as intermediaries to stimulate dopamine receptors without requiring conversion to dopamine. This bypasses the metabolic pathway of L-DOPA, providing sustained dopaminergic stimulation without the dyskinesia and response fluctuations associated with L-DOPA therapy.
Solution Approach 2:
By modifying the catecholamine structure with specific substituents, the patent creates compounds with optimized receptor binding properties and metabolic stability, enabling sustained dopaminergic activity without the adverse effects of L-DOPA.
3Object-affected harmful factors
If selective D2-agonists are used, then dyskinesia is reduced, but efficacy in late PD is insufficient
Solution Approach 1:
The patent designs compounds that act as mixed D1/D2 receptor agonists, providing multi-functional dopaminergic stimulation. This dual agonism maintains efficacy in late-stage Parkinson's disease by activating both D1 and D2 receptor pathways, while the optimized structure reduces dyskinesia compared to traditional L-DOPA therapy.
Data Source
Figure 1
Figure 2
AI summary
The present invention relates to novel catecholamine derivatives of Formula I, to processes for their preparation, pharmaceuticalcompositions containing them and to their use in therapy.